HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2299-2308

  Ji, Meiying ^a   Lee, Eun Jeoung ^a   Kim, Ki Bae ^a   Kim, Yangmi ^a   Sung, Rohyun ^a   Lee, Sang Jeon ^a   Kim, Don Soo ^a   Park, Seon Mee ^a  

^a Chungbuk National University College of Medicine   (South Korea)

Author keywords

Colon cancer; Epithelial mesenchymal transition; Transforming growth factor 1; Trichostatin A; Valproic acid

Indexed keywords

MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TRICHOSTATIN A; UVOMORULIN; VALPROIC ACID; VIMENTIN; CADHERIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; CARCINOMA CELL; CELL INVASION ASSAY; CELL MIGRATION ASSAY; COLON CARCINOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DETERMINATION; DRUG DETERMINATION; DRUG EFFECT; E CADHERIN GENE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; IMMUNOFLUORESCENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIMENTIN GENE; WESTERN BLOTTING; CARCINOMA; CELL MOTION; COLON TUMOR; DRUG EFFECTS; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; TUMOR INVASION;

CADHERINS; CARCINOMA; CELL MOVEMENT; COLONIC NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HT29 CELLS; HUMANS; HYDROXAMIC ACIDS; MICROSCOPY, CONFOCAL; NEOPLASM INVASIVENESS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; VALPROIC ACID; VIMENTIN;

EID: 84927127599     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3879     Document Type: Article

References (43)

1. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG and Lee JS: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 44:11-24, 2012.
2. Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, Chen CW and Wang JY: Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol 100:736-743, 2009.
3. Lee SJ, Choi SY, Kim WJ, Ji M, Lee TG, Son BR, Yoon SM, Sung R, Lee EJ, Youn SJ and Park SM: Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients. Diagn Pathol 8:99, 2013.
4. He X, Chen Z, Jia M and Zhao X: Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS One 8:e70858, 2013.
5. Findlay VJ, Wang C, Watson DK and Camp ER: Epithelial-tomesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther 21:181-187, 2014.
6. Mariadason JM: HDACs and HDAC inhibitors in colon cancer. Epigenetics 3:28-37, 2008.
7. Chen X, Wong P, Radany E and Wong JY: HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24:689-699, 2009.
8. Meng J, Zhang HH, Zhou CX, Li C, Zhang F and Mei QB: The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncol Rep 28:384-388, 2012.
9. Hsu YF, Sheu JR, Lin CH, Yang DS, Hsiao G, Ou G, Chiu PT, Huang YH, Kuo WH and Hsu MJ: Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochim Biophys Acta 1820:104-115, 2012.
10. Xiong H, Du W, Zhang YJ, Hong J, Su WY, Tang JT, Wang YC, Lu R and Fang JY: Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoterassociated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog 51:174-184, 2012.
11. Habold C, Poehlmann A, Bajbouj K, Hartig R, Korkmaz KS, Roessner A and Schneider-Stock R: Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J Cell Mol Med 12:607-621, 2008.
12. Marchion D and Munster P: Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 7:583-598, 2007.
13. Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F and Gambacorti-Passerini C: Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer 124:1990-1996, 2009.
14. DI Fazio P, Montalbano R, Quint K, Alinger B, Kemmerling R, Kiesslich T, Ocker M and Neureiter D: The pan-deacetylase inhibitor panobinostat modulates the expression of epithelialmesenchymal transition markers in hepatocellular carcinoma models. Oncol Lett 5:127-134, 2013.
15. Shah P, Gau Y and Sabnis G: Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res Treat 143:99-111, 2014.
16. Srivastava RK, Kurzrock R and Shankar S: MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 9:3254-3266, 2010.
17. Taylor MD, Liu Y, Nagji AS, Theodosakis N and Jones DR: Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells. J Thorac Cardiovasc Surg 139:1224-1232, 2010.
18. Meng F, Sun G, Zhong M, Yu Y and Brewer MA: Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer. Br J Cancer 108:579-586, 2013.
19. Kaimori A, Potter JJ, Choti M, Ding Z, Mezey E and Koteish AA: Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 52:1033-1045, 2010.
20. Xiao W, Chen X, Liu X, Luo L, Ye S and Liu Y: Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells. J Cell Mol Med 18:646-655, 2014.
21. Chen X, Xiao W, Chen W, Luo L, Ye S and Liu Y: The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells. Cell Death Dis 4:e884, 2013.
22. Yoshikawa M, Hishikawa K, Marumo T and Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-tomesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 18:58-65, 2007.
23. Kong D, Ahmad A, Bao B, Li Y, Banerjee S and Sarkar FH: Histone deacetylase inhibitors induce epithelial-to-mesenchymal tranasition in prostate cancer cells. PLoS One 7:e45045, 2012.
24. Giudice FS, Pinto DS Jr, Nör JE, Squarize CH and Castilho RM: Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One 8:e58672, 2013.
25. Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, Wang H, Cai SH and Du J: Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta 1833:663-671, 2013.
26. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D, Park DY, Iafrate AJ, Zukerberg LR and Chung DC: Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 138:1406-1417, 2010.
27. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428, 2009.
28. Wu Y, Zhang X, Salmon M and Zehner ZE: The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells 12:905-918, 2007.
29. Uchida H, Maruyama T, Nishikawa-Uchida S, Oda H, Miyazaki K, Yamasaki A and Yoshimura Y: Studies using an in vitro model show evidence of involvement of epithelialmesenchymal transition of human endometrial epithelial cells in human embryo implantation. J Biol Chem 287:4441-4450, 2012.
30. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-5552, 2007.
31. Gujral TS and MacBeath G: A system-wide investigation of the dynamics of Wnt signaling reveals novel phases of transcriptional regulation. PLoS One 5:e10024, 2010.
32. Elzagheid A, Algars A, Bendardaf R, Lamlum H, Ristamaki R, Collan Y, Syrjanen K and Pyrhonen S: E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol 12:4304-4309, 2006.
33. Céspedes MV, Larriba MJ, Pavón MA, Alamo P, Casanova I, Parreño M, Feliu A, Sancho FJ, Muñoz A and Mangues R: Site-dependent E-cadherin cleavage and nuclear translocation in metastatic colorectal cancer model. Am J Pathol 177:2067-2079, 2010.
34. Han AC, Soler AP, Tang CK, Knudsen KA and Salazar H: Nuclear localization of E-cadherin expression in Merkel cell carcinoma. Arch Pathol Lab Med 124:1147-1151, 2000.
35. Moon KC, Cho SY, Lee HS, Jeon YK, Chung JH, Jung KC and Chung DH: Distinct expression patterns of E-cadherin and beta-catenin in signet ring cell carcinoma components of primary pulmonary adenocarcinoma. Arch Pathol Lab Med 130:1320-1325, 2006.
36. Gervais ML, Henry PC, Saravanan A, Burry TN, Gallie BL, Jewett MA, Hill RP, Evans AJ and Ohh M: Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clearcell renal cell carcinoma. Lab Invest 87:1252-1264, 2007.
37. Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, Chetty R and Woodgett JR: Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol 21:271-281, 2008.
38. Serra S, Salahshor S, Fagih M, Niakosari F, Radhi JM and Chetty R: Nuclear expression of E-cadherin in solid pseudopapillary tumors of the pancreas. JOP 8:296-303, 2007.
39. Ordonez NG: Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma. Hum Pathol 34:749-755, 2003.
40. Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS and Cristofanilli M: Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. Cancer 116:2760-2767, 2010.
41. Lei W, Zhang K, Pan X, Hu Y, Wang D, Yuan X, Shu G and Song J: Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition. Int J Biochem Cell Biol 42:1489-1497, 2010.
42. Manoguerra AS, Erdman AR, Woolf AD, Chyka PA, Caravati EM, Scharman EJ, Booze LL, Christianson G, Nelson LS, Cobaugh DJ and Troutman WG: Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 46:661-676, 2008.
43. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and Pelicci PG: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71-76, 2005.